Charles Schwab
WHWK

Charles Schwab’s Whitehawk Therapeutics WHWK Stock Holding History

Charles Schwab’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37,075
Closed -$86.8K – 3692
2024
Q1 		$86.8K Sell
37,075
-8,294
-18% -$16K ﹤0.01% 3318
2023
Q4 		$91.6K Hold
45,369
– – ﹤0.01% 3354
2023
Q3 		$220K Hold
45,369
– – ﹤0.01% 3270
2023
Q2 		$310K Buy
45,369
+4,150
+10% +$32.3K ﹤0.01% 3218
2023
Q1 		$298K Hold
41,219
– – ﹤0.01% 3089
2022
Q4 		$529K Buy
41,219
+4,966
+14% +$64.8K ﹤0.01% 2993
2022
Q3 		$513K Sell
36,253
-3,597
-9% -$47.3K ﹤0.01% 2996
2022
Q2 		$491K Buy
+39,850
New +$592K ﹤0.01% 3090
2021
Q2 		– Sell
-856
Closed -$17K – 3552
2021
Q1 		$17K Hold
856
– – ﹤0.01% 3485
2020
Q4 		$13K Hold
856
– – ﹤0.01% 3390
2020
Q3 		$20K Hold
856
– – ﹤0.01% 3312
2020
Q2 		$17K Hold
856
– – ﹤0.01% 3301
2020
Q1 		$8K Hold
856
– – ﹤0.01% 3221
2019
Q4 		$9K Hold
856
– – ﹤0.01% 3175
2019
Q3 		$9K Hold
856
– – ﹤0.01% 3176
2019
Q2 		$12K Hold
856
– – ﹤0.01% 3209
2019
Q1 		$12K Buy
+856
New +$36.8K ﹤0.01% 3192

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's WHWK Position: Q2 2024 in Review

Charles Schwab sold out of Whitehawk Therapeutics (WHWK) in Q2 2024, closing a stake of 37,075 shares — an estimated $86.8K sold.

Charles Schwab first reported a position in WHWK in Q1 2019 and held it in 17 quarters. The position peaked at $529K in Q4 2022. 65 funds tracked by Wall St. Rank hold WHWK as of Q2 2024.

  • Charles Schwab reported no remaining Whitehawk Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Charles Schwab sold 37,075 Whitehawk Therapeutics shares in Q2 2024, an estimated $86.8K.
  • Charles Schwab first reported a position in Whitehawk Therapeutics in Q1 2019 and held it in 17 quarters.
  • Charles Schwab's Whitehawk Therapeutics position peaked at $529K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.